Lilly Announces Latest Clinical Data from Global Trials of Pirtobrutinib in CLL/SLL and Mantle Cell Lymphoma

Eli Lilly (LLY.US) announced on Monday the latest clinical data from its global trial of the anticancer drug pirtobrutinib, according to Zhitong Finance APP.

Earlier this year,pirtobrutinibApproved as Jaypirca under the FDA's accelerated approval pathway(pirtobrutinib), for the treatment of adult patients with relapsed or refractory MCL who have received at least two prior lines of systemic therapy. The drug also received accelerated approval for the treatment of adult patients with CLL/SLL who have received at least two prior therapies.

Latest data presented at the 65th American Society of Hematology meeting supportspirtobrutinibThe role in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).

The oral presentation provided detailed updates on the latest long-term follow-up data for CLL/SLL patients. The dataset includes 282 patients previously treated with a Bruton's tyrosine kinase inhibitor.

The efficacy results of the cohort showed that those who receivedpirtobrutinibThe overall response rate in treated patients was 81.6% (95% CI: 76.5, 85.9), including partial responses with lymphocytosis (PR-L).

With a median follow-up of 27.5 months, the median progression-free survival (PFS) was 19.4 months (95% CI: 16.6, 22.1). With a median follow-up of 29.3 months, the median overall survival (OS) could not be estimated.

In MCL cases, the overall response rate for patients treated with pirtobrutinib was 49.3%, with a complete response rate of 15.8% (n=24) and a partial response rate of 33.6% (n=51). The median PFS and OS were 5.6 months and 23.5 months, respectively.